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Variants of the osteopontin (OPN) gene have been associated with systemic lupus erythematosus (SLE) susceptibility and cytokine
proﬁlesinSLEpatients.ItisnotknownwhethertheseallelesareassociatedwithspeciﬁcclinicalphenotypesinSLE.Westudied252
well-characterized SLE patients from a multiethnic cohort, genotyping the rs11730582, rs28357094, rs6532040, and rs9138 SNPs
in the OPN gene. Ancestry informative markers were used to control for genetic ancestry. The SLE-risk allele rs9138C in the 3 
UTR region was associated with photosensitivity in lupus patients across all ancestral backgrounds (meta-analysis OR = 3.2, 95%
CI = 1.6–6.5, P = 1.0 × 10
−3). Additionally, the promoter variant rs11730582C demonstrated suggestive evidence for association
with two hematologic traits: thrombocytopenia (OR = 2.1, P = 0.023) and hemolytic anemia (OR = 2.6, P = 0.036). These
clinical associations with SNPs in the promoter and 3  UTR regions align with previously reported SLE-susceptibility SNPs in
OPN and suggest potential roles for these variants in antibody-mediated cytopenias and skin inﬂammation in SLE.
1.Introduction
Systemic lupus erythematosus (SLE) is an autoimmune
disease characterized by the production of autoantibodies to
nuclear antigens. The severity, prognosis, and manifestations
of the disease are highly variable between patients. SLE
commonly involves the hematopoietic, skin, musculoskele-
tal, and renal systems. Involvement of the respiratory, car-
diovascular, and central nervous systems can also occur, and
diﬀerent patients typically exhibit diﬀerent patterns of organ
system involvement. Approximately ninety percent of cases
are females, with the typical age of onset being in the
reproductive years [1].
Genetic factors play a signiﬁcant role in the pathogenesis
of SLE. Familial studies have shown that 10–12% of SLE pa-
tientshaveanaﬀectedﬁrst-degreerelative,whichisatwenty-
to ﬁftyfold increase in occurrence when compared to the
generalpopulation[2].Studiesinmonozygoticanddizygotic
twins have shown that the disease co-occurs in monozygotic
twins 24–69% of the time, while only 2–9% of the time in
dizygotic twins [3]. While this data supports a strong genetic
inﬂuence on SLE susceptibility, the varied concordance in
diﬀerent studies of monozygotic twins also implies a sig-
niﬁcant role for additional factors beyond genetic sequence
variations. Genome-wide association and candidate gene
studies have been successful in identifying a number of genes
implicated in SLE susceptibility, including those for im-
munoglobulin receptors (FcγR) [4], and transcription fac-
tors such as STAT4 [5]a n dI R F 5[ 6, 7].
In order to discover mechanisms of SLE pathogenesis,
candidate genes that produce cytokines are of interest [8].
Variants of the osteopontin (OPN or SPP1) gene have been
associated with SLE susceptibility [9–11]. OPN is a secreted
extracellularmatrixcelladhesionglycoprotein.ItsroleinSLE
may be explained through its diverse immunological func-
tions, which include macrophage chemotaxis, T-Helper type
1 lymphocyte response, and B-cell activation [12]. High
levels of OPN have been documented in biopsies of inﬂamed2 Journal of Biomedicine and Biotechnology
tissues in SLE and other autoimmune diseases [13, 14]. In
addition, studies have shown that an increased plasma OPN
level is correlated with increased SLE disease activity [15].
In mouse models, OPN is essential for the production of
interferon-alpha (IFN-α)[ 16]. IFN-α levels are elevated in
manySLEpatients[17,18],andhighIFN-αisaheritablerisk
factor for SLE [19]. In previous work, we have shown that
the SLE risk-associated allele of OPN rs9138C was associated
with higher levels of serum OPN and IFN-α in young
women and men with SLE [20]. This phenomenon in which
a genetic risk factor for SLE impacts cytokine proﬁles has
been demonstrated for a number of other SLE-risk loci as
well [21–23].
There is some precedent for SLE-risk loci being associ-
ated with particular SLE clinical features [24–26] although
much work remains to be done in this area. While OPN
genetic variants have been linked to SLE susceptibility, little
is currently known about whether OPN alleles are associated
with particular clinical manifestations of SLE. One study
demonstrated an association between lymphadenopathy and
rs7687316 in the promoterregion in Europeanancestryindi-
viduals [10]. Another study of 81 SLE patients of European-
American ancestry demonstrated an association between
a synonymous change in exon 7 with avascular necrosis
and renal insuﬃciency [11]. We hypothesized that certain
clinical subphenotypes of SLE would be associated with
the presence of SLE risk alleles of the OPN gene, and that
some of these associations would extend across diﬀerent
ancestral backgrounds. By identifying clinical traits associ-
ated with OPN alleles, we hoped to gain insight into both
potential mechanisms of SLE pathogenesis and the diversity
of clinical presentations between patients.
2.MaterialsandMethods
2.1. Patients and Samples. 252 patients clinically diagnosed
with SLE were recruited from the outpatient rheumatology
clinic at the University of Chicago and at Rush University,
including 145 African-American, 67 European-American, 23
Hispanic-American, and 11 Asian-American patients. All
patients fulﬁlled the American College of Rheumatology
(ACR) Criteria score of 4 or higher [27]. The Institutional
Review Boards at the respective institutions approved the
study, and all subjects provided written informed consent.
Table 1 contains demographic information on the patients
included in the study.
2.2. Clinical Data. A comprehensive medical history relating
to lupus and other immunologic illnesses was taken at
the time of enrollment. ACR classiﬁcation criteria for SLE
were documented for each patient using patient history and
laboratory testing. The “hematologic disease” ACR criterion
is composite criteria composed which can be fulﬁlled by the
presence of leukopenia, lymphopenia, thrombocytopenia,
or hemolytic anemia. We chose to study each of these he-
matologic criteria separately, rather than studying the com-
posite “hematologic disease” criterion. Similarly, the “im-
munologic disease” criterion is a composite of anti-Smith
antibodies, anti-dsDNA antibodies, and antiphospholipid
Table 1: Demographic characteristics of the SLE population
studied.
Self-reported ancestry N
African American 145
European American 67
Hispanic American 23
Asian-American 11
Age yrs.
Range 18–87
Mean 44.38
Std. deviation 13.11
Gender n (%)
Males 21 (8.33%)
Females 231 (91.67%)
antibodies, and we studied each of these individual compo-
nents separately. Autoantibodies were assayed for all subjects
in the University of Chicago Clinical Immunology Labora-
tory, using standard procedures and cutoﬀ points for posi-
tive values. Anti-Sm and antiphospholipid antibodies were
measuredusingELISA,andanti-dsDNAwasmeasuredusing
the Crithidia luciliae method. Complete blood counts were
done to assess blood cell subset counts. The prevalence of the
various common clinical manifestations associated with SLE
in our cohort is illustrated in Table 2.
2.3. Genotyping. We genotyped four haplotype-tagging and/
or SLE-associated SNPs within the OPN gene region.
rs11730582 and rs28357094 are both in the 5  promoter
region of the OPN gene located on chromosome 4, and both
have been previously associated with SLE. rs6532040 is in
an intron and has not been previously associated with SLE
susceptibility.rs9138hasbeenpreviouslyassociatedwithSLE
susceptibility and serum cytokines in SLE patients and is
in the 3  UTR region of osteopontin. Genotyping was per-
formed using ABI Taqman assays-by-design primers for
probes for each of the four SNPs on an ABI 7900HT PCR
machine. Table 3 describes the genotype data at the four
SNPs for patients in our study. All SNPs demonstrated the
expected Hardy-Weinberg proportions when tested in each
ancestral background individually (HW P value >0.01 for
all), supporting the validity of the genotype data.
2.4. Statistical Analysis. The genetic and clinical databases
were merged, and STATA 8.2 was used for statistical analysis
to determine associations between phenotypes and the four
SNPs. The four SNPs chosen were not in high-linkage
disequilibrium with each other (r-squared <0.35 for each
pairwise SNP combination in each ancestral background),
andthustherewerenostronghaplotypesformedacrossthese
4 SNPs, and each SNP was analyzed separately. Because the
frequency of the SNPs of interest and the frequency of SLE
manifestations both vary by race, ancestry as a confounder
had to be addressed in this study. To control this potential
confounding, we ﬁrst analyzed each self-reported ancestral
background separately. Then, we used ancestry informativeJournal of Biomedicine and Biotechnology 3
Table 2: Prevalence of clinical features in diﬀerent ancestral backgrounds.
Clinical feature African Americans European Americans Hispanic Americans Asian Americans
Malar rash 0.49 0.53 0.70 0.60
Discoid rash 0.31 0.08 0.26 0.50
Photosensitivity 0.08 0.08 0.13 0.30
Oral ulcers 0.35 0.32 0.48 0.25
Arthritis 0.85 0.86 0.81 1.00
Serositis 0.34 0.35 0.43 0.20
Hemolytic anemia∗ 0.10 0.05 0.20 0.25
Lymphopenia∗ 0.83 0.76 1.00 0.75
Thrombocytopenia 0.14 0.05 0.00 0.10
Leukopenia 0.39 0.23 0.13 0.50
Neurologic symptoms 0.14 0.12 0.09 0.00
Anti-Smith antibody 0.41 0.18 0.39 0.40
Anti-DNA antibody 0.51 0.56 0.22 0.60
Antiphospholipid antibody∗ 0.42 0.43 1.00 0.25
ANA 0.98 0.91 0.95 0.88
∗Data for these ACR criteria were only available for 130 SLE patients—84 African Americans, 37 European Americans, 5 Hispanic Americans, and 4 Asian
Americans.
Table 3: Minor allele frequencies across diﬀerent ancestral backgrounds.
SNP African Americans European Americans Hispanic Americans Asian Americans
rs11730582 C 0.148 0.402 0.304 0.364
rs28357094 G 0.059 0.265 0.239 0.045
rs6532040 G 0.427 0.321 0.239 0.136
rs9138 C 0.164 0.265 0.250 0.500
markers in a principal component analysis to generate
quantitative values representing proportional ancestry. The
full details of this analysis and graph of the ﬁrst two principal
components are shown in [28]. Principal components were
used as a covariate in the logistic regression analyses to
control for diﬀerences in proportional ancestry between
SLE cases. In the case that a similar eﬀect was observed
across ancestral backgrounds, we performed a meta-analysis
across groups using the same control for proportional
ancestrybetweengroups.Logisticregressionsforcategorical-
dependent variables were performed in the STATA 8.2 pro-
gram. Clinical manifestations were the dependent variables
and were recorded as binary variables representing the pres-
ence or absence of each of the 11 ACR classiﬁcation criteria.
The four diﬀerent OPN SNPs were used as the independent
variables, and each SNP was modeled in an additive fashion.
P values shown in the paper are uncorrected for multiple
comparisons. A P value <0.0031 would withstand a Bonfer-
roni correction for multiple comparisons, adjusting for the
number of clinical variables tested in our study. Associations
detected in this study which have a P value of less than
0.05 but did not meet the threshold P value of 0.0031 were
described as “suggestive” or “possible” associations.
3. Results
3.1. rs9138 C Allele Is Associated with Photosensitivity.
Photosensitivity was present in 8.64% (21/243) of patients
in the cohort. As shown in Table 4, photosensitivity was
strongly associated with the SLE risk allele rs9138 C across
all ancestral backgrounds (meta-analysis OR = 3.245, P =
0.001, 95% CI = 1.609–6.542). This association would with-
stand a Bonferroni correction for the number of phenotypes
analyzed in this study. The prevalence of photosensitivity
did not diﬀer signiﬁcantly between ancestral backgrounds
(7.59% in African Americans and 7.58 in European Amer-
icans, Table 2). Photosensitivity was not associated with the
principal components representing genetic ancestry within
each ancestral background, supporting the idea that dif-
ferences in proportional ancestry or admixture were not
confounding the analysis. Additionally, a similar pattern
of association between rs9138 C and photosensitivity was
observed in each ancestral background analyzed separately.
3.2. rs11730582 C Allele Is Associated with Thrombocytope-
nia and Hemolytic Anemia. The SLE risk-associated single
nucleotide polymorphism rs11730582 C demonstrated a
suggestiveassociationwithtwodiﬀerenthematologicalman-
ifestations (Table 4). Thrombocytopenia was associated with
the rs11730582 C allele (meta-analysis OR = 2.12, P =
0.023, 95% CI = 1.11–4.04). Data for hemolytic anemia was
available for 127 patients, as the samples from one of the
sites did not assess this hematologic subcategory. A possible
associationbetweenrs11730582Candhemolyticanemiawas
observed in the patients in whom this data was available
(meta-analysis OR = 2.55, P = 0.036, 95% CI = 1.06–6.13).4 Journal of Biomedicine and Biotechnology
Table 4: Associations between clinical features and OPN SNPs.
SNP Photosensitivity Thrombocytopenia Hemolytic anemia
OR 95% CI P value OR 95% CI P value OR 95% CI P value
rs11730582 C 1.74 0.90–3.39 0.101 2.12 1.11–4.04 0.023 2.55 1.06–6.13 0.036
rs28357094 G 0.99 0.42–2.39 0.999 0.52 0.16–1.68 0.273 0.26 0.03–2.05 0.200
rs6532040 G 0.59 0.28–1.22 0.156 1.00 0.53–1.88 0.999 1.31 0.53–3.22 0.553
rs9138 C 3.25 1.61–6.54 0.001 1.58 0.79–3.13 0.195 0.99 0.37–2.65 0.977
OR: odds ratio, 95% CI: 95% conﬁdence interval of the odds ratio.
As might be expected, presence of thrombocytopenia and
presence of hemolytic anemia were correlated with each
other (P = 0.0013). In conditional analyses, each hemato-
logic phenotype demonstrated similar suggestive evidence
for association with rs11730582 C when conditioned on the
other, and a higher odds ratio for association was observed
forrs11730582Cinpatientswhoexhibitedbothhematologic
traits (OR = 3.37, P = 0.033).
4. Discussion
SLE is a clinically and genetically heterogeneous disease. It
seems likely that the striking clinical heterogeneity is due
at least in part to diﬀerences in the genetic determinants
of disease between patients. We demonstrate an association
between the most consistent SLE risk allele in the 3  UTR
region and photosensitivity and additionally show suggestive
evidence that the promoter region of the gene is associated
with hematologic phenotypes in SLE patients. This ﬁnding
of two independent associations in the promoter and 3 
UTR regions has been observed previously with the OPN
gene. In a case control study, this model of two independent
associations was the best ﬁt [10], and in our own previous
work, we observed an antibody association with the pro-
moterandaserumcytokineassociationwiththe3  UTRSNP
rs9138 [20].
One limitation of this study is that a relatively small
cohort with robust and detailed clinical data was analyzed.
Thus, we were only able to detect associations with large-
eﬀect sizes and cannot exclude any potential moderate
strength associations that we did not detect in this study.
Using a Bonferroni correction for multiple comparisons, the
photosensitivity association with rs9138 C would remain
signiﬁcant, while the two possible hematologic associations
with rs11730582 C would not. The genotype frequencies in
our SLE cases were similar to those previously published in
large-scale case-control experiments [9].
Interestingly, rs11730582 C was associated with two
distinct hematological manifestations which share some
aspects of pathogenesis: hemolytic anemia and thrombocy-
topenia. Previous studies have established that thrombocy-
topenia and hemolytic anemia in lupus typically have an
autoantibody-mediated pathogenesis. 90% of lupus patients
with thrombocytopenia have been shown to possess anti-
bodies directed against either the glycoprotein IIb/IIIa or
thrombopoietin receptor [29]. Hemolytic anemia in SLE is
frequently a Coomb’s test-positive, antibody-mediated he-
molytic anemia. OPN in its secreted form functions as a
cytokine involved in B-cell activation and plays a role in
antibody production [14]. We have previously demonstrated
the rs11730582 C allele was associated with an increased
prevalence of antiribonuclear protein autoantibodies (anti-
RNP) [20]. These data in aggregate support a role for the
promoter region in autoantibody formation in SLE.
Although the rs9138 C allele was not associated with
hematological ﬁndings, it was strongly associated with pho-
tosensitivity in lupus patients. This association was particu-
larlyinterestinggivenourpreviouslypublishedﬁndingofthe
association of rs9138 C with increased levels of both osteo-
pontin and IFN-α in SLE patients [20]. Numerous studies
have indicated a central role of plasmacytoid dendritic cells
(PDCs) and their secretion of IFN-α in SLE pathogenesis
[30, 31]. Additionally, OPN is essential for IFN-α production
by murine PDCs [14]. It is known that cutaneous lupus is
an autoimmune process characterized by photosensitivity,
ultraviolet-light-induced apoptosis of keratinocytes, and an
inﬂammatory inﬁltrate in superﬁcial and deep compart-
ments of the skin [30]. The histopathologic accumulation
of PDCs and their subsequent secretion of IFN-α have been
demonstrated in these photosensitive lesions [25, 32]. In
light of these ﬁndings, the statistically signiﬁcant association
between the OPN gene variant rs9138 C and the clinical
manifestation of photosensitivity may be supported by a
cytokine-mediated pathogenic mechanism.
The rs11730582 C and rs9138 C alleles of the OPN gene
have been previously and independently associated with in-
creased risk of lupus. In this study, we ﬁnd that both of these
alleles are independently associated with distinct clinical
features in SLE patients, supporting divergent roles for
theseallelesinthepathogenesisofSLE.Thisworkwillinform
future genetic studies of the locus and provides intriguing
hypotheses regarding the molecular pathogenesis of SLE
which can be followed up in mechanistic studies.
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